A strong and growing portfolio

We are an integrated biotechnology company dedicated to rare diseases. Our research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases.
We also market and make available across Europe, the Middle East, North Africa and Russia a portfolio of specialty and rare disease products for partner companies. In addition, we manufacture the drug substance for the haemophilia treatment ReFacto AF/Xyntha® for the global market.

Pipeline Programs Core Products ReFacto Manufacturing Partner Products

Core Products

These are proprietary products or products where Sobi has global or regional rights.

Read more
Partner Products

Partner Products comprise about 40 products which are commercialized on behalf of specialty and rare disease partner companies.

Read more
ReFacto Manufacturing

Sobi is the global supplier of the drug substance for ReFacto AF®/XYNTHA®, a drug sold by Pfizer for the treatment of hemophilia A.

Read more

Opouštíte webové stránky SOBI

Společnost SOBI již dále nenese odpovědnost za obsah ani funkčnost internetových stránek jiných subjektů.

Přejete si opustit stránky?

Ano    Ne